Secure skin closure is an integral step of nearly every surgical procedure. If the closure device does not provide the strength and support required by the skin tissue, the wound edges may separate, providing a potential pathway for bacterial contamination, which can lead to infection, suboptimal cosmesis, and low patient satisfaction.^1,170,171

DERMABOND ADVANCED™ Topical Skin Adhesive can add strength and protection to an incision.

• Strength: When used in addition to sutures, DERMABOND ADVANCED™ was shown ex vivo to add 75% more strength to wound closure than sutures alone¹
• Microbial Barrier: DERMABOND ADVANCED™ provides a microbial barrier with 99% protection in vitro for at least 72 hours against organisms commonly responsible for surgical site infections (SSIs)*^,117,192
• Inhibition of bacteria: DERMABOND ADVANCED™ demonstrated in vitro inhibition of gram-positive bacteria (MRSA & MRSE) and gram-negative bacteria (E. coli)^†

A patented, thicker formula with a unique blend of plasticizers and an initiator for precise control

• Plasticizers increase flexibility and 3-dimensional strength for secure wound closure and patient comfort²¹³
• Initiator enables consistent setting time across various conditions and skin types²¹³

DERMABOND ADVANCED™ is part of the DERMABOND® Portfolio. Each product in the DERMABOND® Portfolio provides strong, protective, and efficient closure.^1,117,192

The products in the DERMABOND® Portfolio are supported by more clinical evidence, outcomes data, and publications than any other topical skin adhesive.¹⁹³

DERMABOND ADVANCED™ Topical Skin Adhesive is a skin closure device used to hold closed easily approximated skin edges of wounds from surgical incisions or laceration.

• DERMABOND ADVANCED™ has a patented, proprietary chemical formulation that has been shown to provide excellent strength and microbial protection versus other commercially available topical skin adhesives.¹
• Compared with many other topical skin adhesives, DERMABOND ADVANCED™ provides enhancements such as single-layer application, reduced drying time, and an ergonomically designed applicator for improved handling during application.¹

DERMABOND ADVANCED™ may be used in conjunction with but not in place of deep dermal stitches.

Secure skin closure is an integral step of nearly every surgical procedure. If the closure device does not provide the strength and support required by the skin tissue, the wound edges may separate, providing a potential pathway for bacterial contamination, which can lead to infection, suboptimal cosmesis, and low patient satisfaction.^1,170,171

Excellent outcomes can be achieved if a skin closure device:

• Provides the strength to maintain skin edges so that they remain approximated and level
• Distributes tension along the entire incision, adding uniform strength to the incision and preventing skin gaps from forming when the skin is stressed
• Creates a strong, flexible barrier to prevent bacteria from entering the incision until the epidermis has fully healed

DERMABOND ADVANCED™ Topical Skin Adhesive has a propriety formulation consisting of:

• A highly purified 2-octylcyanoacrylate monomer, which, after polymerization is stronger, more flexible, and less brittle than other cyanoacrylates¹
• A chemical initiator in the applicator tip to ensure consistent, reliable polymerization times²⁰²
• Formulation additives to enhance strength, flexibility, and adherence to the skin²⁰²

The unique and proprietary formulation of DERMABOND ADVANCED™ helps protect patients by maintaining wound integrity.^117,192 DERMABOND ADVANCED™ is supported by more clinical evidence and real-world data than any competing product.¹⁹³

Strength

Sutures alone

Sutures with DERMABOND ADVANCED™ Adhesive

Skin gaps form at a force of 182 mmHg²¹²

Maintains skin approximation at a force of 320 mmHg²¹²

Microbial Barrier

With 99% protection in vitro for at least 72 hours against organisms commonly responsible for SSIs*^,1,117

24, 48, 72 hours following application of DERMABOND ADVANCED™

Inhibition of Bacteria

DERMABOND ADVANCED™ demonstrated in vitro inhibition of gram-positive bacteria (MRSA and MRSE) and gram-negative bacteria (E coli)^†,1

Hospitalization Costs

In a retrospective analysis of over 155,000 C-sections,^§

• Hospitalization costs for the group in which DERMABOND® Topical Skin Adhesive was used were on average lower by $500²⁰⁵
• Patients on whom DERMABOND® Adhesive was used had lower nonprophylactic antibiotic usage after Day 4 compared to patients closed with sutures or staples²⁰⁵

Length of Hospitalization

In a retrospective study of 1,3000 CABG patients post-operative hospital days were significantly reduced from a median of 13 days to 9 days for patients in whom DERMABOND® Adhesive was used to close the skin.²⁰⁵